APR 01, 2017 2:08 PM PDT

First Approved Drug to Show Promise Against Mesothelioma

WRITTEN BY: Xuan Pham

A cancer antibody is showing promising results against mesothelioma, one of the most lethal silent cancers. The antibody is known as pembrolizumab (Keytruda) and works as a second-line immunotherapy agent to destroy the cancer. Researchers say this is the first approved drug to show effectiveness against mesothelioma.

Image: firstwessex.com

As one of the most aggressive cancer types, mesothelioma is a cancer of the lining of the lung. Uniquely, this cancer is caused by exposure to manmade products containing the carcinogen asbestos. When breathed into the lungs, asbestos fibers get trapped and cause scarring and inflammation, triggering serious health conditions like mesothelioma. Though rare nowadays in the US, cases of mesotheliomas are still rampant in other parts of the world due to unregulated use of materials containing asbestos. The disease has a poor prognosis, with less than one-year survival rates after diagnosis.

"There have been a lot of studies looking at different drugs, but researchers have not seen positive results. But we've found this new class of drugs, checkpoint inhibitors, seems to be more effective than what's been available in the past,” said Dr. Evan Alley, a medical oncology specialist at the Penn Presbyterian Medical Center of the University of Pennsylvania Health System in Philadelphia, and the study’s lead author.

In a study of 25 patients with mesothelioma who were given pembrolizumab every 2 weeks for 2 years, the team observed significant changes in cancer progression. This included tumor shrinkage in 14 of the patients. The average survival time was extended to 18 month, of which the first 6 months seem to show no progression of cancer.

"Most patients who receive a second-line therapy have a life expectancy of about 6 or 7 months, so to have four patients still ongoing at 2 years is very encouraging,” said Dr. Alley.

Pembrolizumab targets the programmed cell death 1 (PD-1) receptor, a protein that’s responsible for preventing the immune system from attacking its own cells. Cancers can take advantage of this system by making its own proteins that bind to PD-1, which shuts down the body’s ability to kill the cancer. As an immunotherapy, pembrolizumab boosts the body’s ability to kill the cancer again. The drug is already approved for the treatment of several other types of cancer, including non-small cell lung cancer, melanoma, and some head and neck cancers.

While promising, the results of this study are limited by the small sample size. More validation studies are necessary to confirm the anticancer effects of pembrolizumab against mesothelioma. But as it is, chemotherapy as a first-line defense, and pembrolizumab as a second-line defense seems to be a promising strategy.

“This study provides evidence that some patients can have long-term disease control with this drug, which we haven't seen before. We need to better understand what we can do next to make immunotherapy more effective for more patients,” said Dr. Alley.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 07, 2020
Immunology
JAN 07, 2020
"Good" T Cells Can Go "Bad," But in the Case of Cancer, That's A Good Thing
T cells may be able to reach their full potential in the fight against cancer with a little nudge. In 2010, scientists first observed CD4+ T cells transiti...
JAN 15, 2020
Cell & Molecular Biology
JAN 15, 2020
Cell Division Research Reveals More About a Protein That's Elevated in Cancer
Cell division is a carefully regulated process, cancer is the result when it gets out of control....
JAN 20, 2020
Neuroscience
JAN 20, 2020
Ovarian Cancer Protein Accelerates Alzheimer's Neurodegeneration
Around 21,000 people in the US are diagnosed with ovarian cancer every year, while an estimated 5.8 million Americans have Alzheimer’s. Now, research...
JAN 27, 2020
Genetics & Genomics
JAN 27, 2020
Finding Cancer-Promoting Genes Using Machine Learning
Machine learning algorithms are increasingly being applied to the vast amount of genetic data that has been generated over the past decade....
FEB 24, 2020
Cancer
FEB 24, 2020
Could NRF2 trigger hepatomegaly?
Research published today in the Journal of Hepatology suggests that the protein responsible for antioxidant defenses in humans may adversely affect th...
FEB 24, 2020
Drug Discovery & Development
FEB 24, 2020
Leukemic Drugs May Target Lung Cancer
Two approved therapeutics for treating leukemia are currently being investigated for treatment-resistant lung cancer.  The findings were based on a li...
Loading Comments...